Shares of Exact Sciences Co. (NASDAQ:EXAS - Get Free Report) traded down 4.3% during trading on Tuesday . The company traded as low as $55.92 and last traded at $56.01. 652,498 shares were traded during trading, a decline of 65% from the average session volume of 1,890,406 shares. The stock had previously closed at $58.51.
Analysts Set New Price Targets
EXAS has been the topic of a number of research analyst reports. Benchmark reiterated a "buy" rating and issued a $65.00 target price on shares of Exact Sciences in a report on Monday. Canaccord Genuity Group decreased their target price on Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. William Blair reissued an "outperform" rating on shares of Exact Sciences in a research report on Monday. Craig Hallum reduced their price target on shares of Exact Sciences from $82.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Finally, Citigroup dropped their price objective on shares of Exact Sciences from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $72.94.
Check Out Our Latest Report on EXAS
Exact Sciences Stock Performance
The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The company has a 50 day moving average price of $57.57 and a 200 day moving average price of $58.98. The company has a market capitalization of $10.03 billion, a PE ratio of -46.32 and a beta of 1.24.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Exact Sciences's quarterly revenue was up 12.8% on a year-over-year basis. Equities analysts forecast that Exact Sciences Co. will post -1.13 EPS for the current year.
Insider Buying and Selling at Exact Sciences
In other Exact Sciences news, CEO Kevin T. Conroy purchased 19,500 shares of Exact Sciences stock in a transaction dated Wednesday, November 13th. The shares were bought at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the transaction, the chief executive officer now owns 1,074,191 shares in the company, valued at $55,159,707.85. This represents a 1.85 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.36% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Exact Sciences
A number of institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. grew its holdings in shares of Exact Sciences by 130.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 22,801 shares of the medical research company's stock valued at $1,281,000 after purchasing an additional 12,912 shares during the last quarter. Kieckhefer Group LLC bought a new position in Exact Sciences during the 4th quarter worth $188,000. Harbor Capital Advisors Inc. grew its stake in Exact Sciences by 35.3% during the 4th quarter. Harbor Capital Advisors Inc. now owns 95,827 shares of the medical research company's stock worth $5,385,000 after buying an additional 24,992 shares during the last quarter. Diversified Trust Co increased its position in Exact Sciences by 5.9% in the fourth quarter. Diversified Trust Co now owns 12,639 shares of the medical research company's stock worth $710,000 after buying an additional 708 shares during the period. Finally, Everence Capital Management Inc. bought a new stake in Exact Sciences in the fourth quarter valued at $356,000. Institutional investors own 88.82% of the company's stock.
About Exact Sciences
(
Get Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
